AU2018243691B2 - Heterocyclic compound - Google Patents
Heterocyclic compound Download PDFInfo
- Publication number
- AU2018243691B2 AU2018243691B2 AU2018243691A AU2018243691A AU2018243691B2 AU 2018243691 B2 AU2018243691 B2 AU 2018243691B2 AU 2018243691 A AU2018243691 A AU 2018243691A AU 2018243691 A AU2018243691 A AU 2018243691A AU 2018243691 B2 AU2018243691 B2 AU 2018243691B2
- Authority
- AU
- Australia
- Prior art keywords
- group
- substituted
- alkyl
- substituents selected
- membered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762476970P | 2017-03-27 | 2017-03-27 | |
| US62/476,970 | 2017-03-27 | ||
| PCT/US2018/024043 WO2018183112A1 (en) | 2017-03-27 | 2018-03-23 | Heterocyclic compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2018243691A1 AU2018243691A1 (en) | 2019-10-24 |
| AU2018243691B2 true AU2018243691B2 (en) | 2022-05-12 |
Family
ID=63671942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018243691A Active AU2018243691B2 (en) | 2017-03-27 | 2018-03-23 | Heterocyclic compound |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10543212B2 (enExample) |
| EP (1) | EP3600327A4 (enExample) |
| JP (1) | JP7249950B2 (enExample) |
| KR (1) | KR102638678B1 (enExample) |
| CN (1) | CN110799190B (enExample) |
| AU (1) | AU2018243691B2 (enExample) |
| CA (1) | CA3058182A1 (enExample) |
| TW (1) | TWI789381B (enExample) |
| WO (1) | WO2018183112A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7249950B2 (ja) | 2017-03-27 | 2023-03-31 | カーデュリオン・ファーマシューティカルズ・リミテッド・ライアビリティ・カンパニー | ヘテロ環化合物 |
| JP7569688B2 (ja) | 2017-12-22 | 2024-10-18 | ハイバーセル，インコーポレイテッド | ホスファチジルイノシトールリン酸キナーゼ阻害剤としてのアミノピリジン誘導体 |
| WO2020068846A1 (en) * | 2018-09-25 | 2020-04-02 | Heterocyclic Compound | Heterocyclic compound |
| JP7447098B2 (ja) * | 2018-09-25 | 2024-03-11 | カーデュリオン・ファーマシューティカルズ・インコーポレイテッド | アミノピリミジン化合物 |
| WO2020140054A1 (en) | 2018-12-28 | 2020-07-02 | Spv Therapeutics Inc. | Cyclin-dependent kinase inhibitors |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| EP4048664A1 (en) * | 2019-10-25 | 2022-08-31 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| SI4097097T1 (sl) | 2020-01-29 | 2025-04-30 | Gilead Sciences, Inc. | Spojine, ki modulirajo glp-1r |
| KR102563111B1 (ko) * | 2020-03-18 | 2023-08-04 | 주식회사 엘지화학 | Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법 |
| WO2021187886A1 (ko) * | 2020-03-18 | 2021-09-23 | 주식회사 엘지화학 | Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법 |
| JP2023543038A (ja) | 2020-09-28 | 2023-10-12 | カーデュリオン・ファーマシューティカルズ・インコーポレイテッド | 縮合ヘテロアリール化合物およびＣａＭＫＩＩ阻害剤としてのその使用 |
| EP4247804A1 (en) | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| WO2022192428A1 (en) | 2021-03-11 | 2022-09-15 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| EP4304712A1 (en) | 2021-03-11 | 2024-01-17 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| WO2022216094A1 (ko) * | 2021-04-08 | 2022-10-13 | 주식회사 엘지화학 | Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법 |
| MX2023012418A (es) | 2021-04-21 | 2023-10-31 | Gilead Sciences Inc | Compuestos de modulacion de glp-1r de carboxi-bencimidazol. |
| US20250170101A1 (en) * | 2021-12-29 | 2025-05-29 | Psy Therapeutics, Inc. | Monoacylglycerol lipase inhibitors and use thereof for the treatment and management of pain and related conditions |
| EP4457213A4 (en) | 2021-12-29 | 2025-12-17 | Psy Therapeutics Inc | INHIBITION OF MONOACYLGLYCEROL LIPASE (MAGL) |
| CN114621312B (zh) * | 2022-03-24 | 2022-11-15 | 陕西师范大学 | 一种寡肽烷基侧链的选择性修饰方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002011724A2 (en) * | 2000-08-08 | 2002-02-14 | Ortho-Mcneil Pharmaceutical, Inc. | Neuroprotective 2-pyridinamine compositions and related methods |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60136731D1 (de) | 2000-09-20 | 2009-01-08 | Ortho Mcneil Pharm Inc | Pyrazine derivate als tyrosin kinase modulatoren |
| AU2004261484A1 (en) | 2003-07-30 | 2005-02-10 | Cyclacel Limited | 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors |
| JP2007504229A (ja) | 2003-09-02 | 2007-03-01 | メルク エンド カムパニー インコーポレーテッド | 代謝調節型グルタミン酸受容体−５のモジュレーターとしてのビピリジルアミン類およびエーテル類 |
| AU2008236670B2 (en) * | 2007-04-05 | 2011-12-01 | Amgen Inc. | Aurora kinase modulators and method of use |
| WO2009032703A1 (en) | 2007-08-28 | 2009-03-12 | Irm Llc | 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors |
| WO2010038081A2 (en) * | 2008-10-03 | 2010-04-08 | Astrazeneca Ab | Heterocyclic derivatives and methods of use thereof |
| GB0821307D0 (en) * | 2008-11-21 | 2008-12-31 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
| EP2638018A1 (en) * | 2010-11-09 | 2013-09-18 | Cellzome Limited | Pyridine compounds and aza analogues thereof as tyk2 inhibitors |
| EP2763976B1 (en) | 2011-10-05 | 2016-05-18 | Merck Sharp & Dohme Corp. | 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
| AU2013250378B2 (en) | 2012-04-17 | 2016-01-14 | Fujifilm Corporation | Nitrogen-containing heterocyclic compound or salt thereof |
| JP7249950B2 (ja) * | 2017-03-27 | 2023-03-31 | カーデュリオン・ファーマシューティカルズ・リミテッド・ライアビリティ・カンパニー | ヘテロ環化合物 |
-
2018
- 2018-03-23 JP JP2019553090A patent/JP7249950B2/ja active Active
- 2018-03-23 AU AU2018243691A patent/AU2018243691B2/en active Active
- 2018-03-23 CN CN201880021628.6A patent/CN110799190B/zh active Active
- 2018-03-23 WO PCT/US2018/024043 patent/WO2018183112A1/en not_active Ceased
- 2018-03-23 US US15/933,889 patent/US10543212B2/en active Active
- 2018-03-23 EP EP18777887.3A patent/EP3600327A4/en active Pending
- 2018-03-23 KR KR1020197031604A patent/KR102638678B1/ko active Active
- 2018-03-23 CA CA3058182A patent/CA3058182A1/en active Pending
- 2018-03-26 TW TW107110319A patent/TWI789381B/zh active
-
2020
- 2020-01-27 US US16/773,730 patent/US11197858B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002011724A2 (en) * | 2000-08-08 | 2002-02-14 | Ortho-Mcneil Pharmaceutical, Inc. | Neuroprotective 2-pyridinamine compositions and related methods |
Also Published As
| Publication number | Publication date |
|---|---|
| TWI789381B (zh) | 2023-01-11 |
| JP7249950B2 (ja) | 2023-03-31 |
| AU2018243691A1 (en) | 2019-10-24 |
| US20200230137A1 (en) | 2020-07-23 |
| WO2018183112A1 (en) | 2018-10-04 |
| US20180280389A1 (en) | 2018-10-04 |
| CN110799190A (zh) | 2020-02-14 |
| TW201904959A (zh) | 2019-02-01 |
| KR20200027917A (ko) | 2020-03-13 |
| CA3058182A1 (en) | 2018-10-04 |
| US10543212B2 (en) | 2020-01-28 |
| CN110799190B (zh) | 2024-04-19 |
| US11197858B2 (en) | 2021-12-14 |
| KR102638678B1 (ko) | 2024-02-19 |
| EP3600327A4 (en) | 2020-10-28 |
| JP2020515575A (ja) | 2020-05-28 |
| EP3600327A1 (en) | 2020-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018243691B2 (en) | Heterocyclic compound | |
| AU2015250610B2 (en) | Isoindoline-1-one derivatives as cholinergic muscarinic M1 receptor positive alloesteric modulator activity for the treatment of Alzheimers disease | |
| KR20210014108A (ko) | Parp7 억제제로서의 피리다지논 | |
| EA016204B1 (ru) | Производные триазолпиразинов, применимые в качестве противораковых агентов | |
| US12435063B2 (en) | Nitrogen containing heterocycles as CDK12 inhibitors | |
| WO2017003995A1 (en) | TBK/IKKε INHIBITOR COMPOUNDS AND USES THEREOF | |
| US11795172B2 (en) | Substituted imidazo[1,2-b]pyridazines and [1,2,4]triazolo[4,3-b]pyridazines as CaMKII inhibitors | |
| WO2021020585A1 (ja) | 複素環化合物 | |
| AU2019350717B2 (en) | Aminopyrimidine compound | |
| HK40043646B (en) | Heterocyclic compound | |
| HK40043646A (en) | Heterocyclic compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |